Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

RAPT Therapeutics Inc

Healthcare US RAPT

NoneUSD
0.00(0%)

Last update at 2026-04-09T21:02:34.402473Z

Day Range

--
LowHigh

52 Week Range

3.9527.35
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap142.23M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-126.78700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 1.53M
  • Diluted EPS TTM-3.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -83.83800M -69.20400M -51.90200M -42.33700M -36.14700M
Minority interest - - - - -
Net income -81.88100M -68.20800M -52.89200M -42.99700M -36.14700M
Selling general administrative 20.24M 16.04M 12.77M 8.72M 5.18M
Selling and marketing expenses - - - - -
Gross profit 1.53M 3.81M 5.04M - -
Reconciled depreciation 1.05M 1.00M 1.12M 1.33M 1.24M
Ebit -86.84200M -70.20500M -54.33700M -44.95900M -36.94700M
Ebitda -85.79500M -69.20900M -53.21400M -43.62900M -35.71000M
Depreciation and amortization 1.05M 1.00M 1.12M 1.33M 1.24M
Non operating income net other 1.96M 0.00500M 1.31M - -
Operating income -85.79500M -69.20900M -53.21400M -43.62900M -36.94700M
Other operating expenses 87.32M 73.02M 58.26M 43.63M 36.95M
Interest expense 1.05M 1.00M 2.44M 2.62M 0.00000M
Tax provision - 0.00000M 0.99M 0.66M -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.95700M -0.99600M 0.99M 0.66M 0.80M
Total revenue 1.53M 3.81M 5.04M 0.00000M 0.00000M
Total operating expenses 87.32M 73.02M 58.26M 43.63M 36.95M
Cost of revenue - - - - -
Total other income expense net 1.96M 0.00500M 1.31M 1.29M 0.80M
Discontinued operations - - - - -
Net income from continuing ops -83.83800M -69.20400M -52.89200M -42.99700M -36.14700M
Net income applicable to common shares -83.83800M -69.20400M -52.89200M -42.99700M -36.14700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 173.33M 266.21M 198.64M 118.97M 84.60M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.92M 3.63M 3.32M 4.09M 3.12M
Total liab 26.29M 21.04M 12.26M 14.79M 11.48M
Total stockholder equity 147.03M 245.17M 186.38M 104.18M 73.12M
Deferred long term liab - - 2.66M 3.05M -
Other current liab 14.21M 8.69M 0.25M 0.33M 0.47M
Common stock 0.00300M 0.00300M 0.00300M 0.00200M 0.00200M
Capital stock 0.00300M 0.00300M 0.00300M 0.00200M 0.00200M
Retained earnings -484.68200M -367.88400M -284.04600M -214.84200M -161.95000M
Other liab - - 2.66M 3.05M 2.23M
Good will - - - - -
Other assets 0.00000M 4.04M 2.92M 0.39M 0.39M
Cash 47.48M 38.95M 24.03M 24.92M 77.38M
Cash and equivalents - - - - -
Total current liabilities 21.84M 14.22M 9.60M 11.74M 9.26M
Current deferred revenue - - 1.02M 4.10M 4.00M
Net debt -40.57200M -29.95600M -24.02700M -24.91800M -77.38300M
Short term debt 2.45M 2.17M 6.33M 4.93M 3.64M
Short long term debt - - - - -
Short long term debt total 6.91M 8.99M - - -
Other stockholder equity 631.61M 613.07M 470.63M 319.20M 150.45M
Property plant equipment - 2.54M 2.74M 2.98M 3.71M
Total current assets 161.78M 252.69M 192.97M 115.60M 80.51M
Long term investments - - - - -
Net tangible assets - 245.17M 186.38M 104.18M 73.12M
Short term investments 111.38M 210.12M 165.63M 86.59M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 5.18M 3.37M 2.00M 2.38M 1.14M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.10M -0.02600M -0.20600M -0.17700M 0.02M
Additional paid in capital - - - - -
Common stock total equity - 0.00300M 0.00300M 0.00200M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -367.88400M -284.04600M -214.84200M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.87M 4.04M 2.92M 0.39M 0.39M
Deferred long term asset charges - - - - -
Non current assets total 11.55M 13.52M 5.66M 3.37M 4.10M
Capital lease obligations 6.91M 8.99M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -44.64500M -80.59200M -87.03700M -0.84300M -3.50000M
Change to liabilities 2.18M -2.49900M 3.35M 4.74M 1.44M
Total cashflows from investing activities -45.49000M -81.34700M -87.43500M -0.84300M -3.50000M
Net borrowings - - - - -
Total cash from financing activities 131.18M 141.48M 75.46M 49.90M 52.73M
Change to operating activities -3.51800M -1.79900M -1.00500M -0.60300M -0.65300M
Net income -83.83800M -69.20400M -52.89200M -42.99700M -36.14700M
Change in cash 14.92M -0.89100M -52.46500M 13.59M 16.28M
Begin period cash flow 24.03M 24.92M 77.38M 63.80M 47.52M
End period cash flow 38.95M 24.03M 24.92M 77.38M 63.80M
Total cash from operating activities -70.77100M -61.02600M -40.49100M -35.47400M -32.95300M
Issuance of capital stock 129.79M 139.46M 74.56M 49.90M 52.73M
Depreciation 1.05M 1.00M 1.12M 1.33M 1.24M
Other cashflows from investing activities - - - 0.04M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 131.18M 141.48M 0.90M 0.80M 52.73M
Other cashflows from financing activities 1.39M 2.02M -87.43500M 13.58M 52.47M
Change to netincome 11.89M 11.48M 8.44M 2.06M 1.17M
Capital expenditures 0.84M 0.76M 0.40M 0.89M 3.50M
Change receivables - - - - -
Cash flows other operating -1.75800M -1.79900M -1.00500M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 14.92M -0.89100M -52.46500M - -
Change in working capital -1.33500M -4.29800M 2.34M 4.13M 0.78M
Stock based compensation 11.26M 9.95M 8.69M 2.05M 1.17M
Other non cash items 2.09M 1.53M 0.25M 0.02M -0.01400M
Free cash flow -71.61600M -61.78100M -40.88900M -36.36200M -36.45300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RAPT
RAPT Therapeutics Inc		 - -% - - - 411.22 2.18 677.37 -1.3366
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

RAPT Therapeutics Inc

561 Eccles Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Brian Russell Wong M.D., Ph.D. CEO, Pres & Director 1972
Mr. Rodney K. B. Young CFO, Principal Accounting Officer & Sec. 1963
Dr. William Ho Chief Medical Officer 1966
Steve Young Ph.D. VP of Technology NA
Dr. Dirk G. Brockstedt Ph.D. Chief Scientific Officer 1969
Ms. Gwen R. Carscadden Chief HR Officer 1961
Dr. Paul Kassner Sr. VP of Quantitative & Computational Biology 1967
Dr. David Wustrow Sr. VP of Drug Discovery & Preclinical Devel. 1959
Ms. Jennifer Nicholson Sr. VP of Regulatory Affairs & Quality Assurance NA
Dr. Brian Russell Wong M.D., Ph.D. CEO, President & Director 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions